Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Authors
Keywords
-
Journal
CELL
Volume 184, Issue 21, Pages 5309-5337
Publisher
Elsevier BV
Online
2021-10-09
DOI
10.1016/j.cell.2021.09.020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Understanding and treating the inflammatory adverse events of cancer immunotherapy
- (2021) Michael Dougan et al. CELL
- Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing
- (2021) Li Wang et al. CLINICAL CANCER RESEARCH
- Identification of bacteria-derived HLA-bound peptides in melanoma
- (2021) Shelly Kalaora et al. NATURE
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The exposome and health: Where chemistry meets biology
- (2020) Roel Vermeulen et al. SCIENCE
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- (2020) Laura Strauss et al. Science Immunology
- Microbiome analyses of blood and tissues suggest cancer diagnostic approach
- (2020) Gregory D. Poore et al. NATURE
- Moving towards personalized treatments of immune-related adverse events
- (2020) Khashayar Esfahani et al. Nature Reviews Clinical Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
- (2020) Zia Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The human tumor microbiome is composed of tumor type–specific intracellular bacteria
- (2020) Deborah Nejman et al. SCIENCE
- Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
- (2020) Akash Mitra et al. Nature Communications
- Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy
- (2020) Kaustav P Shah et al. Cancer Immunology Research
- CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
- (2020) Miguel Gaspar et al. Cancer Immunology Research
- Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells
- (2020) Yifan Zhou et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
- (2020) Patrick Boland et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
- (2020) Chaoxu Zhang et al. Frontiers in Oncology
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers
- (2020) Jennifer L. McQuade et al. Current Oncology Reports
- Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
- (2020) Ying Jing et al. Nature Communications
- Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice
- (2020) Hao Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention
- (2020) Spencer C Wei et al. Cancer Discovery
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- (2019) Alessio Cortellini et al. Journal for ImmunoTherapy of Cancer
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
- (2019) Lorenzo Castagnoli et al. ONCOGENE
- The microbiome, cancer, and cancer therapy
- (2019) Beth A. Helmink et al. NATURE MEDICINE
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Modulating the microbiome to improve therapeutic response in cancer
- (2019) Jennifer L McQuade et al. LANCET ONCOLOGY
- Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
- (2019) Ying Zhu et al. GUT
- Sex hormones and anticancer immunity
- (2019) Berna C. Özdemir et al. CLINICAL CANCER RESEARCH
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity
- (2019) Hiroshi Yano et al. IMMUNOLOGY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
- (2019) Daniel Johnson et al. Cancer Immunology Research
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
- (2019) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling
- (2019) Koen A. Marijt et al. Journal for ImmunoTherapy of Cancer
- Tackling the Complexity of the Exposome: Considerations from the Gunma University Initiative for Advanced Research (GIAR) Exposome Symposium
- (2019) Pei Zhang et al. Metabolites
- Treg-mediated acquired resistance to immune checkpoint inhibitors
- (2019) Reem Saleh et al. CANCER LETTERS
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
- (2019) Erick Riquelme et al. CELL
- Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
- (2019) David Bomze et al. JAMA Oncology
- Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
- (2019) Ludovic Fournel et al. CANCER LETTERS
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance
- (2019) Xiaohu Zheng et al. NATURE IMMUNOLOGY
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
- (2019) Robert D. Leone et al. SCIENCE
- A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
- (2019) Zhichen Sun et al. Nature Communications
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer
- (2019) Zuzana Snahnicanova et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
- (2018) Álvaro de Mingo Pulido et al. CANCER CELL
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients
- (2018) Qiang Ma et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Perturbation of metabolic pathways mediates the association of air pollutants with asthma and cardiovascular diseases
- (2018) Ayoung Jeong et al. ENVIRONMENT INTERNATIONAL
- Cancer related circulating and tumor-associated neutrophils - subtypes, sources and function
- (2018) Merav E. Shaul et al. FEBS Journal
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
- (2018) Janet Retseck et al. Journal of Translational Medicine
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
- (2018) Neibla Priego et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC
- (2018) Fernando Costa Santini et al. Cancer Immunology Research
- Subgroup-specific immune and stromal microenvironment in medulloblastoma
- (2018) Michael Bockmayr et al. OncoImmunology
- Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
- (2018) Franz L. Ricklefs et al. Science Advances
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- (2018) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- The Exposome: Molecules to Populations
- (2018) Megan M. Niedzwiecki et al. Annual Review of Pharmacology and Toxicology
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs)
- (2018) Sorim Nam et al. Biomolecules & Therapeutics
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
- (2018) Omar Hasan Ali et al. EUROPEAN JOURNAL OF CANCER
- Molecular mimicry and autoimmunity
- (2018) Manuel Rojas et al. JOURNAL OF AUTOIMMUNITY
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
- (2018) Laura C Cappelli et al. RHEUMATOLOGY
- TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
- (2018) Ankur Chakravarthy et al. Nature Communications
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- From the exposome to mechanistic understanding of chemical-induced adverse effects
- (2017) Beate I. Escher et al. ENVIRONMENT INTERNATIONAL
- Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
- (2017) Rivka R. Colen et al. INVESTIGATIONAL NEW DRUGS
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Analysis ofFusobacteriumpersistence and antibiotic response in colorectal cancer
- (2017) Susan Bullman et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice
- (2017) Kathleen M. Kokolus et al. OncoImmunology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
- (2017) Alexandre Reuben et al. npj Genomic Medicine
- CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
- (2016) B. Lo et al. BLOOD
- Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
- (2016) Edward W. Roberts et al. CANCER CELL
- Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
- (2016) Jing Liu et al. CANCER RESEARCH
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune system and cancer evasion strategies: therapeutic concepts
- (2016) S. Muenst et al. JOURNAL OF INTERNAL MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
- (2016) Chunwan Lu et al. OncoImmunology
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
- (2015) J. J. Rojas et al. CLINICAL CANCER RESEARCH
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
- (2014) A. Sucker et al. CLINICAL CANCER RESEARCH
- Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
- (2014) Jia Xue et al. IMMUNITY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer
- (2014) W. Cao et al. JOURNAL OF IMMUNOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Nature of Nurture: Refining the Definition of the Exposome
- (2013) Gary W. Miller et al. TOXICOLOGICAL SCIENCES
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- The exposome: from concept to utility
- (2012) Christopher Paul Wild INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2010) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Environment-Wide Association Study (EWAS) on Type 2 Diabetes Mellitus
- (2010) Chirag J. Patel et al. PLoS One
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Environment and Disease Risks
- (2010) S. M. Rappaport et al. SCIENCE
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
- (2008) B. Kavanagh et al. BLOOD
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
- (2008) C A Crane et al. ONCOGENE
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now